Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer.
AffiliationDepartment of Medical Oncology, Beaumont Hospital, Dublin, Ireland. firstname.lastname@example.org.
MetadataShow full item record
CitationAnti-VEGF Strategies - from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer. 2012, 18 (19):2680-701 Curr. Pharm. Des.
JournalCurrent pharmaceutical design
AbstractTumour angiogenesis (formation of new blood vessels supporting tumour growth and metastasis) is a result of complex interactions between the tumour and the surrounding microenvironment. Targeting tumours with anti-angiogenic therapy remains an exciting area of preclinical and clinical studies. Although many significant advances have been achieved and the clinical use of anti-angiogenic drugs is now well recognized in many solid malignancies, these therapies fall short of their anticipated clinical benefits and leave many unanswered questions like exact mechanism of action, patients' selection and monitoring response to anti-angiogenic drugs. Tumour angiogenesis is controlled by complex signaling cascades and ongoing research into molecular mechanisms of tumour angiogenesis not only helps to understand its basic mechanisms but hopefully will identify new therapeutic targets. In 2012, both monoclonal antibodies and small molecule tyrosine kinase inhibitors remain the two major clinically useful therapeutic options that interfere with tumour angiogenesis in many solid malignancies.
- Current overview of angiogenesis inhibitors.
- Authors: Ellis LM
- Issue date: 2004 Aug
- Therapeutic options to target angiogenesis in human malignancies.
- Authors: Herbst RS
- Issue date: 2006 Nov
- Role of tumour angiogenesis in haematological malignancies.
- Authors: Medinger M, Passweg J
- Issue date: 2014
- EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
- Authors: Press MF, Lenz HJ
- Issue date: 2007
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
- Authors: Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, Komuves L, Peale F, Ferrara N
- Issue date: 2012 Aug